Compare TILE & GENB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TILE | GENB |
|---|---|---|
| Founded | 1973 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 1994 | N/A |
| Metric | TILE | GENB |
|---|---|---|
| Price | $25.54 | $13.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $36.00 | $25.00 |
| AVG Volume (30 Days) | ★ 624.4K | 510.8K |
| Earning Date | 05-01-2026 | 05-03-2026 |
| Dividend Yield | ★ 0.31% | N/A |
| EPS Growth | ★ 32.43 | N/A |
| EPS | ★ 1.96 | N/A |
| Revenue | ★ $1,386,854,000.00 | N/A |
| Revenue This Year | $7.00 | N/A |
| Revenue Next Year | $5.46 | N/A |
| P/E Ratio | $13.08 | ★ N/A |
| Revenue Growth | ★ 5.41 | N/A |
| 52 Week Low | $17.31 | $11.00 |
| 52 Week High | $35.11 | $13.95 |
| Indicator | TILE | GENB |
|---|---|---|
| Relative Strength Index (RSI) | 36.14 | 59.01 |
| Support Level | $24.72 | $11.21 |
| Resistance Level | $27.13 | N/A |
| Average True Range (ATR) | 0.92 | 1.10 |
| MACD | 0.12 | 0.14 |
| Stochastic Oscillator | 31.22 | 85.97 |
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment. Its products include: ESD, Acoustic, Extreme Wear, and Quick Installation System (nTx).
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.